Current and Emerging Pharmacotherapies for the Treatment of Pulmonary Arterial Hypertension in Infants

Overview

Journal Expert Opin Pharmacother

Publisher Informa Healthcare

Specialty Pharmacology

Date 2023 Sep 14

PMID 37707346

Authors

Matthew F Pizzuto

Matthew M Laughon

Wesley M Jackson

Affiliations

Soon will be listed here.

Abstract

Introduction: Pulmonary hypertension (PH) is a complex condition that encompasses an array of underlying disease processes and affects a diverse population of infants, including those with congenital heart disease, congenital diaphragmatic hernia, persistent PH of the newborn, and those with lung disease such as bronchopulmonary dysplasia. While there are treatments available to adults with PH, limited data exists for infants, especially for the newer medications. Therapies that target the three main pathophysiologic pathways of pulmonary hypertension appear to benefit infants, but which are best for each individual disease process is unclear.

Areas Covered: A review of the therapies to treat pulmonary hypertension is covered in this article including the prostacyclin pathway, endothelin pathway, and the nitric oxide pathway. Other adjunctive treatments are also discussed. Findings are based on a PubMed literature search of research papers spanning 1990-2023 and a search of ongoing trials registered with clinicaltrials.gov.

Expert Opinion: Overall therapies seem to improve outcomes with most infants with PH. However, given the diverse population of infants with PH, it is imperative to understand the basis for the PH in individual patients and understand which therapies can be applicable. Further research into tailored therapy for the specific populations is warranted.

References

Barst R . A review of pulmonary arterial hypertension: role of ambrisentan. Vasc Health Risk Manag. 2007; 3(1):11-22. PMC: 1994051. View

Patel N . Use of milrinone to treat cardiac dysfunction in infants with pulmonary hypertension secondary to congenital diaphragmatic hernia: a review of six patients. Neonatology. 2012; 102(2):130-6. DOI: 10.1159/000339108. View

Paul G, Gibbs J, Boobis A, Abbas A, Wilkins M . Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005; 60(1):107-12. PMC: 1884910. DOI: 10.1111/j.1365-2125.2005.02383.x. View

Tissot C, Beghetti M . Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc Health Risk Manag. 2009; 5(1):325-31. PMC: 2672461. DOI: 10.2147/vhrm.s3222. View

. Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS). Pediatrics. 1997; 99(6):838-45. DOI: 10.1542/peds.99.6.838. View

Suesaowalak M, Cleary J, Chang A . Advances in diagnosis and treatment of pulmonary arterial hypertension in neonates and children with congenital heart disease. World J Pediatr. 2010; 6(1):13-31. DOI: 10.1007/s12519-010-0002-9. View

McNamara P, Laique F, Muang-In S, Whyte H . Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J Crit Care. 2006; 21(2):217-22. DOI: 10.1016/j.jcrc.2006.01.001. View

More K, Athalye-Jape G, Rao S, Patole S . Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants. Cochrane Database Syst Rev. 2016; (8):CD010531. PMC: 8588275. DOI: 10.1002/14651858.CD010531.pub2. View

Landzberg M . Congenital heart disease associated pulmonary arterial hypertension. Clin Chest Med. 2007; 28(1):243-53, x. DOI: 10.1016/j.ccm.2006.12.004. View

10.

Kelly L, Ohlsson A, Shah P . Sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst Rev. 2017; 8:CD005494. PMC: 6483280. DOI: 10.1002/14651858.CD005494.pub4. View

11.

Le Duc K, Mur S, Sharma D, Aubry E, Recher M, Rakza T . Prostaglandin E1 in infants with congenital diaphragmatic hernia (CDH) and life-threatening pulmonary hypertension. J Pediatr Surg. 2020; 55(9):1872-1878. DOI: 10.1016/j.jpedsurg.2020.01.008. View

12.

Vijay Kumar J, Setty H, Jayaranganath M, Manjunath C . Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN). Interv Med Appl Sci. 2022; 11(4):216-220. PMC: 9467385. DOI: 10.1556/1646.2020.00004. View

13.

Steinhorn R, Kinsella J, Pierce C, Butrous G, Dilleen M, Oakes M . Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J Pediatr. 2009; 155(6):841-847.e1. DOI: 10.1016/j.jpeds.2009.06.012. View

14.

Lawrence K, Berger K, Herkert L, Franciscovich C, ODea C, Waqar L . Use of prostaglandin E1 to treat pulmonary hypertension in congenital diaphragmatic hernia. J Pediatr Surg. 2018; 54(1):55-59. DOI: 10.1016/j.jpedsurg.2018.10.039. View

15.

OToole S, Irish M, Holm B, Glick P . Pulmonary vascular abnormalities in congenital diaphragmatic hernia. Clin Perinatol. 1996; 23(4):781-94. View

16.

Gupta N, Kamlin C, Cheung M, Stewart M, Patel N . Prostaglandin E1 use during neonatal transfer: potential beneficial role in persistent pulmonary hypertension of the newborn. Arch Dis Child Fetal Neonatal Ed. 2012; 98(2):F186-8. DOI: 10.1136/archdischild-2012-303294. View

17.

Geary C, Whitsett J . Inhaled nitric oxide for oligohydramnios-induced pulmonary hypoplasia: a report of two cases and review of the literature. J Perinatol. 2002; 22(1):82-5. DOI: 10.1038/sj.jp.7210580. View

18.

Steinhorn R, Fineman J, Kusic-Pajic A, Cornelisse P, Gehin M, Nowbakht P . Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial. J Pediatr. 2016; 177:90-96.e3. DOI: 10.1016/j.jpeds.2016.06.078. View

19.

Trottier-Boucher M, Lapointe A, Malo J, Fournier A, Raboisson M, Martin B . Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia. Pediatr Cardiol. 2015; 36(6):1255-60. DOI: 10.1007/s00246-015-1154-0. View

20.

Caputo S, Furcolo G, Rabuano R, Basilicata A, Pilla L, De Simone A . Severe pulmonary arterial hypertension in a very premature baby with bronchopulmonary dysplasia: normalization with long-term sildenafil. J Cardiovasc Med (Hagerstown). 2009; 11(9):704-6. DOI: 10.2459/JCM.0b013e328332e745. View